A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

PURPOSE: UCN-01 (7-hydroxystaurosporine) is a multi-targeted protein kinase inhibitor that exhibits synergistic activity with DNA-damaging agents in preclinical studies. We conducted a Phase I study to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetic, and pha...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Fracasso, Paula M., Williams, Kerry J., Chen, Ronald C., Picus, Joel, Ma, Cynthia X., Ellis, Matthew J., Tan, Benjamin R., Pluard, Timothy J., Adkins, Douglas R., Naughton, Michael J., Rader, Janet S., Arquette, Matthew A., Fleshman, James W., Creekmore, Allison N., Goodner, Sherry A., Wright, Lisa P., Guo, Zhanfang, Ryan, Christine E., Tao, Yu, Soares, Eliane M., Cai, Shi-rong, Lin, Li, Dancey, Janet, Rudek, Michelle A., McLeod, Howard L., Piwnica-Worms, Helen
Format: Artigo
Idioma:Inglês
Publicat: Springer-Verlag 2010
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3102212/
https://ncbi.nlm.nih.gov/pubmed/20694727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1410-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars